Labcorp Guides FY Adj EPS to $18.10-$18.55, Above Consensus
LH sits 26% above its 52-week low of $244.52.
Summary
Labcorp issued full-year adjusted EPS guidance of $18.10 to $18.55, a range that sits above the consensus estimate of $17.95. The midpoint of $18.33 implies roughly 12% growth over the prior year, reflecting confidence in the commercial ramp of new diagnostic products like ColoSense and the Marker genetic testing platform. This follows a series of positive product launches in recent months, including the nationwide availability of ColoSense in June and the Marker platform announcement just two days ago. The guidance suggests management sees sustained momentum from these initiatives and the exclusive genetic testing trial partnership announced in May. With the stock trading near its 52-week high, the raised outlook reinforces the growth narrative and could drive further multiple expansion.
At the time of this announcement, LH was trading at $307.05 on NYSE in the Life Sciences sector, with a market capitalization of approximately $25.2B. The 52-week trading range was $244.52 to $315.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.